Clinical comparison of cefuroxime axetil with cefixime in the treatment of acute bronchitis

American Journal of Therapeutics

Volumn 3, Issue 9, 1996, Pages 622-629

  Arthur, Margaret ^a   McAdoo, Michael ^a   Guerra, Javier ^b   Maloney, Robert ^a   McCluskey, Dennis ^a   Giguere, Gregory ^c   Gomez, Gema ^c   Collins, Jeffrey J ^c  

^a Doctors Inn ^*

^b Doctors Inn   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

acute bronchitis; cefuroxime axetil; controlled clinical trial

Indexed keywords

CEFIXIME; CEFUROXIME AXETIL;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SPUTUM CULTURE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 0029985175     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199609000-00004     Document Type: Article

References (29)

1. De Lozier JE, Gagnon RO: National Ambulatory Care Survey: 1989 Summary. Advanced Data No. 203. National Center for Health Statistics, Hyattsville, MD, 1989.
2. Jacobs RA: Anti-infective chemotherapeutic and antibiotic agents. In: Current Medical Diagnosis and Treatment, 34th ed. (Eds. Tierney LM Jr, McPhee SJ, Papadakis MA), Appleton & Lange, Norwalk, CT, 1995, pp 1288-1333.
3. Snider GL, Faling J, Rennard SI: Chronic bronchitis and emphysema. In: Textbook of Respiratory Medicine, 2nd ed. (Eds. Murray JF, Nadel JA), WB Saunders Company, Philadelphia, 1994, pp 1331-1397.
4. Emmerson AM: Cefuroxime axetil. J Antimicrob Chemother 1988;22:101-104.
5. Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS: Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 1990;34:2075-2080.
6. Murray PR: Antimicrobial activity of seven oral antibiotics against selected community- and hospital-acquired pathogens. Clin Ther 1991;13:224-231.
7. Murray PR, Jones RN, Allen SD, Erwin ME, Fuchs PC, Gerlach EH: Multilaboratory evaluation of the in vitro activity of 13 beta-lactam antibiotics against 1474 clinical isolates of aerobic and anaerobic bacteria. Diagn Microbiol Infect Dis 1993;16:191-203.
8. Washington JA, Jones RN, Gerlach EH, Murray PR, Allen SD, Knapp CC: Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime. Antimicrob Agents Chemother 1993;37: 1696-1700.
9. Nolen TM, Phillips HL, Hutchison J, Cocchetto DM: Comparison of cefuroxime axetil and cefaclor for patients with lower respiratory tract infections presenting to a rural family practice clinic. Curr Ther Res 1988;44:821-829.
10. Schleupner CJ, Anthony WC, Tan J, File TM, Lifland P, Craig W, et al: Blinded comparison of cefuroxime to cefaclor for lower respiratory tract infections. Arch Intern Med 1988;148:343-348.
11. Bugnas B, Pappo M, Chiche D: Efficacité et tolérance du céfuroxime-axetil dano le traitement anbulutoi des bronchi infectieuses. Immunologie 1989;6:245-249.
12. Lenoir G, Chiche D: Ambulatory treatment in general practice of respiratory tract infections in children: ceuroxime axetil vs cefadroxil suspension. Program and Abstracts of the 5th European Congress of Clinical Microbiology and Infectious Diseases, Abstract 1785, Oslo, Norway, September 9-11, 1991.
13. Montane F, Piolat V: Comparison of efficacy and tolerance of cefpodoxime proxetil and cefuroxime axetil in the treatment of acute bronchitis. Program and Abstracts of the International Congress for Infectious Diseases, Abstract 632, Montreal, Canada, July 15-19, 1990.
14. Brogden RN, Campoli-Richards DM: Cefixime: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1989;38:524-550.
15. Finn A, Straughn A, Meyer M, Chubb J: Effect of dose and food on the bioavailability of cefuroxime axetil. Biopharm Drug Dispos 1987;8:519-526.
16. National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Disk Susceptibility Tests. National Committee for Clinical Laboratory Standards, Villanova, PA, 1983.
17. National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. National Committee for Clinical Laboratory Standards, Villanova, PA, 1988.
18. Wise R, Honeybourne D, Andrews JM, Ashby JP: The penetration of cefuroxime into the bronchial mucosa following administration of cefuroxime axetil. Program and Abstracts of the 4th European Congress of Clinical Microbiology, Abstract 762, Nice, France, April 17-20, 1989.
19. Walstad RA, Vilsvik JS, Thurmann-Nielsen E, Griggs JV, Brown GW: Pharmacokinetics of cefuroxime axetil in patients with lower respiratory tract infections. In: A Profile of Cefuroxime Axetil in General Practice. London, UK: Royal College of Physicians, London [Abstract]. 1988:35.
20. Doern GV, Tubert AT: In vitro activity of BAY v 3522, a new oral cephalosporin tested against Haemophilus influenzae and Branhamella catarrhalis. Diagn Microbiol Infect Dis 1990;13:349-352.
21. Doern GV: In vitro activity of ceftibuten against Haemophilus influenzas and Branhamella catarrhalis. Diagn Microbiol Infect Dis 1991;14:75-77.
22. Knapp CC, Washington JA II: In vitro activities of LY163892, cefaclor, and cefuroxime. Antimicrob Agents Chemother 1988;32:131-133.
23. Aguedas AG, Arrieta AC, Stutman HR, Akaniro JC, Marks MI: In vitro activity of cefprozil (BMY 28100) and loracarbef (LY 163892) against pathogens obtained from middle ear fluid. J Antimicrob Chemother 1991;27:311-318.
24. Hayashi I: Serum and sputum concentration and clinical results of cefixime on respiratory tract infection. Chemotherapy 1985;33(Suppl 6):253-267.
25. Gehanno P, Boucot I, Chiche D, Berche P: Treatment of community acquired acute sinusitis: cefuroxime axetil vs cefixime. Med Mal Infect 1991;21:61-65.
26. Tally FP, Desjardins RE, McCarthy EF, Cartwright K: Safety profile of cefixime. Pediatr Infect Dis J 1987;6:976-980.
27. Anonymous: Ceftin. In: Physicians' Desk Reference, 49th ed. (Ed. Sifton DW), Medical Economics Data Production Company, Montvale, NJ, 1995, pp 1097-1100.
28. Harding SM, Williams PO, Ayrton J: Pharmacology of cefuroxime as the 1-acetoxyethyl ester in volunteers. Antimicrob Agents Chemother 1984;25:78-82.
29. Williams PO, Harding SM: The absolute bioavailability of oral cefuroxime axetil in male and female volunteers after fasting and after food. J Antimicrob Chemother 1984;13:191-196.